Wellstar Health System, one of Georgia’s largest and most integrated healthcare systems, announced that the Wellstar Cancer Network was recently recognized nationally as a cancer treatment leader. Honored with an Outstanding Achievement Award from the American College of Surgeons Commission on Cancer and designated as a Care Continuum Center of Excellence by the GO2 Foundation for Lung Cancer, the Wellstar Cancer Network continues to pioneer innovative cancer treatments and technologies to improve outcomes and quality of life for patients.
“Wellstar Health System is dedicated to providing patients with the highest quality of compassionate and personalized care,” said Dr. Michael Andrews, Chief Cancer Officer of the Wellstar Cancer Network. “We are extremely proud of the Wellstar Cancer Network and our team of highly skilled physicians, nurses and oncology support services who excel at treating the spectrum of cancer illnesses with the most advanced, patient-centric technologies and treatments. We are focused on enhancing the health and well-being of everyone we serve, with a commitment to delivering world-class cancer care.”
Wellstar earned an Outstanding Achievement Award for the third consecutive cycle from the American College of Surgeons Commission on Cancer (CoC). The highest honor in the United States awarded to a cancer program, the Wellstar Cancer Network was recognized for achieving excellence in providing care to cancer patients. Award recipients must have received commendation ratings in all seven commendation standards and receive a compliance rating for each of the 27 remaining cancer program standards.
Wellstar Recognized as Cancer Treatment Leader
Published on October 12, 2020
Last updated 02:04 PM October 16, 2020
Wellstar Cancer Care Receives National Recognition with Outstanding Achievement Award, Designated as Care Continuum Center of Excellence for Lung Cancer
The purpose of the award is to raise the bar on quality cancer care, with the ultimate goal of increasing awareness about quality care choices among cancer patients and their loved ones. In addition, the award is intended to:
- Recognize those cancer programs that achieve excellence in providing quality care to cancer patients.
- Motivate other cancer programs to work toward improving their level of care.
- Facilitate dialogue between award recipients and health care professionals at other cancer facilities for the purpose of sharing best practices.
- Encourage honorees to serve as quality care resources to other cancer programs.
“More and more, we’re finding that patients and their families want to know how the health care institutions in their communities compare with one another,” said Lawrence N. Shulman, MD, MACP, chair of the CoC. “They want access to information in terms of who’s providing the best quality of care, and they want to know about overall patient outcomes. Through this recognition program, I’d like to think we’re playing a small but vital role in helping them make informed decisions on their cancer care.”
Wellstar was also recognized by the Care Continuum Centers of Excellence (CCCOE), a program of the GO2 Foundation for Lung Cancer which identifies community hospitals that meet rigorous qualifying criteria and demonstrate collaborative leadership across the lung cancer care continuum. GO2 Foundation formed the Care Continuum Centers of Excellence program to enable patient access to standard of care lung cancer screening, early detection, diagnosis, treatment and survivorship in their local community. Meeting the CCCOE criteria puts member hospitals on par with leading academic and research institutions and provides patients with access to the latest innovations not typically found in community hospitals. The CCCOE program promotes a standard of compassionate and timely care excellence with, as well as treatment options that improve survivorship.
“We are proud and honored to be working with Wellstar Health System as a GO2 Foundation Care Continuum Center of Excellence. Their commitment will help save lives and improve long-term survivorship by giving patients access to high-quality, multidisciplinary care closer to home. They are the example to follow,” says Laurie Fenton Ambrose, co-founder, president and CEO of GO2 Foundation.
Related Articles
Highlights
Genetic Testing: A Critical Tool in Cancer Treatment
It's been over three decades since genetic testing was first introduced as a tool for patients at risk of hereditary cancer syndromes. In its early days, genetic testing was expensive and time-consuming (often taking up to eight weeks for results). Fast forward to today and genetic testing is now a routine part of cancer care. It’s more accessible, comprehensive and, perhaps most importantly, significantly impactful for patients and their families.
Physicians help identify patients who could benefit from genetic testing, especially when someone has a personal or family history of cancer. Genetic testing can improve treatment outcomes, guide preventive care and provide vital information for the patient's family.
Benefits of genetic testing
1. Understanding the cause of cancer
One of the most common questions from patients newly diagnosed with cancer is, "Why did this happen to me?" While many cancers are the result of environmental factors, aging and sporadic mutations, genetic testing can offer a more definitive answer. For patients with hereditary cancer, knowing their cancer is genetically driven can help ease feelings of uncertainty and guilt.
For many, this knowledge brings a sense of empowerment, as they now have the opportunity to make informed decisions regarding their treatment and potential preventive measures for the future. This hereditary cancer risk was present since birth, and there was very little if anything the patient could have done differently throughout their life to prevent their diagnosis.
2. Personalized treatment options
For patients with cancers like breast, ovarian, pancreatic and prostate, identifying genetic mutations (like BRCA mutations) can open the door to personalized therapies. The earlier in the diagnostic process the genetic test is ordered, the quicker the patient can be matched with appropriate treatments.
Knowledge of genetic mutations can also guide surgical decisions. Patients with BRCA-positive breast cancer may be candidates for risk-reducing mastectomy or salpingo-oophorectomy—both of which can lower the risk of future cancers. These decisions are most effective when genetic results are available before surgery.
3. Identification of additional cancer risks
Cancer does not always occur in isolation, especially in patients with hereditary cancer syndromes. For instance, patients with Lynch syndrome, a leading cause of colorectal cancer, are also at increased risk for uterine cancer—up to 60%. If identified before a colon resection, this knowledge could allow a hysterectomy at the same time if necessary, minimizing the risk of a second cancer and optimizing care.
Beyond immediate cancer treatment, genetic testing can also lead to additional screenings that might otherwise be missed. For example, the ATM gene is a known contributor to prostate and breast cancer. But patients with an ATM gene mutation are also at elevated risk for pancreatic cancer. While general population screening is not typically recommended, high-risk patients should begin annual imaging and/or endoscopic ultrasounds as early as age 50 or 10 years before the earliest known pancreatic cancer in their family.
4. Informed decisions for family members
A cancer diagnosis doesn’t only affect the patient—it impacts their entire family. Once a genetic mutation is identified, relatives can undergo testing to assess their own cancer risk and talk to their care teams about screenings.
Testing the affected patient first is the most informative strategy for relatives. Patients with negative genetic test results can be reassured that relatives are not at significant risk for the same diagnosis.
The role of genetic counseling in cancer care
Genetic counselors provide the expertise necessary to interpret complex genetic results, discuss the implications for patients and their families, and offer psychological support throughout the process. Genetic counseling not only helps patients make sense of their genetic test results, but also provides them with the tools to make informed decisions about their health.
Counseling also helps address the emotional and psychological aspects of genetic testing, from potential feelings of anxiety to guilt and even empowerment. Research shows that genetic counseling has a positive impact on patient knowledge, reduces anxiety and can improve overall psychological well-being during a cancer journey.
Highlights
Wellstar Kennestone Earns 5 STS Three-Star Ratings, Joining the Nation’s Elite Cardiac Surgery Programs
Wellstar Kennestone Regional Medical Center has earned three-star ratings—the highest ratings possible—in five cardiac surgery categories from the Society of Thoracic Surgeons (STS), placing it among a select group of programs nationwide achieving top-tier performance across a broad range of procedures and making it the only program in Georgia to achieve this distinction.
The STS Adult Cardiac Surgery Database (ACSD) star rating system is one of the most comprehensive and respected measures of quality in the industry, evaluating outcomes from hundreds of hospitals in North America and serving as a leading benchmark for clinical excellence. A three-star rating indicates performance that is significantly better than the national average in key measures such as survival, complication rates and adherence to evidence-based care.
“The STS three-star rating is the highest distinction a cardiac surgery program can earn, and even a single category is rare. Receiving it in five is extraordinary, and it’s a direct reflection of the trust patients place in Wellstar every day,” said Ketul J. Patel, president and CEO of Wellstar Health System. “Our physicians, clinicians and care teams are setting a national standard for quality and safety, making Wellstar a center of excellence for cardiovascular care. This is one of the many ways that Wellstar’s care teams are improving health outcomes in the Southeast.”
In the previous reporting cycle, the program achieved three-star ratings in four categories—an already rare and notable achievement for cardiac surgery programs nationwide. Building on that success, Wellstar Kennestone has now expanded to five three-star categories, underscoring sustained excellence and a continued commitment to advancing high-quality cardiac care.
Wellstar Kennestone received a three-star overall composite quality rating in five of six evaluated procedure categories:
- Coronary artery bypass grafting (CABG)
- Aortic valve replacement (AVR)
- Combined AVR and CABG procedures
- Mitral valve repair and replacement (MVRR)
- Multi-procedural cardiac surgery
The program also earned a two-star rating in the combined MVRR and CABG category.
“For patients, these ratings translate to better outcomes, fewer complications, improved survival and a smoother recovery after major heart surgery,” said Dr. Barry Mangel, chief of clinical service lines at Wellstar. “Achieving and sustaining this level of performance across multiple complex procedures is extraordinarily rare and reflects a deeply coordinated, team-based approach to care.”
Wellstar Kennestone’s cardiac surgery program brings together a highly integrated team of cardiac surgeons, cardiologists, anesthesiologists, intensivists, perfusionists, advanced practice providers, nurses, technologists and support team members. This collaborative approach enables the team to deliver consistently high-quality, coordinated care for patients with even the most complex heart conditions.
These results reflect a sustained commitment to clinical excellence, continuous improvement and delivering the highest standard of cardiovascular care to every person, every time.
For more information about heart care at Wellstar, visit wellstar.org/heartcare.
Newsroom
BD and Wellstar Advance Patient Care and Safety with Medication Management Powered by AI
BD (Becton, Dickinson and Company), a leading global medical technology company, today announced a strategic partnership with Wellstar Health System to enhance the safety and quality of medication delivery for patients across its hospitals and care facilities.
Through this collaboration, Wellstar is building a more connected approach to medication management from the pharmacy to the bedside by combining BD Pyxis™ Pro medication dispensing technologies with BD Alaris™ Infusion Systems. By adopting the latest in dispensing and infusion technology, Wellstar is empowering clinicians with greater accuracy, real time visibility and streamlined workflows, helping them spend less time on manual processes and more time delivering safe, dependable care to their patients.
Powered by artificial intelligence, the new BD Pyxis™ Pro Dispensing Solution with Analytics in BD Incada™ provides Wellstar with enterprise wide visibility into medication inventory, including on demand insights through natural language queries. Customizable dashboards convert data into actionable intelligence, helping clinicians identify trends to ensure medication availability, reduce medication waste and optimize labor efficiency. And with BD Alaris™ Interoperability, Wellstar clinicians can use barcode scanning to verify patients, medications and smart pumps; send infusion orders directly from the electronic medical record and receive infusion statuses back into the EMR.
“At Wellstar, our focus is on delivering safe, innovative care to every patient, every time,” said Susan Wright, vice president of pharmacy services at Wellstar. “Partnering with BD to implement this technology strengthens our ability to focus on patient-centered programs and empower our teams to deliver care with confidence and compassion.”
Wellstar also participates in the Strategic Development Council for BD’s Medication Management Solutions business, where Wellstar leaders contribute expertise across enterprise pharmacy operations, medication safety, nursing and informatics. This input helps inform and shape future innovation at BD and drives next-generation solutions to meet the real world challenges faced by large, complex healthcare systems.
“BD is proud to partner with Wellstar to advance medication safety and help ensure patients receive the right medications at the right time,” said Connor Bates, worldwide president for medication management solutions at BD. “By integrating BD Pyxis™ and BD Alaris™ technologies, Wellstar is setting an example of how health systems can achieve connected, intelligent medication management that benefits both patients and clinicians.”
This collaboration reflects a shared vision to strengthen safety, efficiency and patient outcomes across the continuum of care, while positioning Wellstar as a leader in leveraging technology to improve the health of the communities it serves.